Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM2510 in Advanced Solid Tumors
NCT05972460Phase 1Unknown
- Sponsor
- ImmuneOnco
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM2510 in solid tumor (advanced stage), sponsored by ImmuneOnco. Primary endpoints: Adverse Events, Dose Limiting Toxicity at 28 days and 2 more. Status: unknown.
02
Drugs
IMM2510
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05972460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972460.